Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Screening a library of FDA-approved and bioactive compounds for antiviral activity against SARS-CoV-2

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.12.30.424862Source: DataRank Database

Screening a library of FDA-approved and bioactive compounds for antiviral activity against SARS-CoV-2 is a research paper published in bioRxiv (Cold Spring Harbor Laboratory) (2020). On theSindex it has a DataRank of 0. It has been cited 4 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access4 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)OA: greenTopics (29)IDs (PubMed)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (23)

Erik Van Dis ORCID,Eddie Wehri ORCID,Lívia H. Yamashiro,Xammy Nguyenla ORCID,Claire Dugast‐Darzacq ORCID

Live enrichment

PubMed:21097893

National Science Foundation

Grant: 1752814

Graduate Research Fellowship Program (GRFP)

greenLicense: https://www.biorxiv.org/about/FAQ#license

repositoryhttps://www.biorxiv.org/content/biorxiv/early/2020/12/30/2020.12.30.424862.full.pdf

publisherhttps://syndication.highwire.org/content/doi/10.1101/2020.12.30.424862

repositoryhttps://figshare.com/articles/journal_contribution/Screening_a_Library_of_FDA-Approved_and_Bioactive_Compounds_for_Antiviral_Activity_against_SARS-CoV_2/14786212

https://doi.org/10.1101/2020.12.30.424862

https://pubs.acs.org/doi/pdf/10.1021/acsinfecdis.1c00017

Fields of Study

0301 basic medicine03 medical and health sciences0303 health sciences

Keywords

synergyremdesivirAntiviral AgentsVaccine RelatedRare DiseasesBiodefenseHumansLungPandemicsdrug repurposingSARS-CoV-2PreventionCOVID-19PneumoniaantiviralEmerging Infectious DiseasesInfectious DiseasesOrphan DrugGood Health and Well Being5.1 PharmaceuticalsMedical MicrobiologyPneumonia & InfluenzaDevelopment of treatments and therapeutic interventionsInfectionBiotechnologyB02

Sustainable Development Goals

SDG 3: 3. Good health